Article Text
Statistics from Altmetric.com
The Endocarditis Working Party of the British Society for Antimicrobial Chemotherapy first issued recommendations for the treatment of streptococcal and staphylococcal endocarditis in 1985.1 Since then numerous reports have been published of the results of treatment with the recommended regimens and with other antibiotics, some of which were not available in 1985, and the American Heart Association has recently reviewed its guidelines for antibiotic treatment.2 Revised diagnostic criteria3 ,4and new therapeutic procedures have also become available and many more patients have had prosthetic valves implanted. We have reviewed our recommendations in light of these developments and our wish to have simplified up to date guidelines that are most appropriate for use in the UK. They are intended to cover more than 90% of the cases of infective endocarditis seen in the UK, which are caused by streptococci, enterococci and staphylococci.
In endocarditis the heart valves may be damaged at an early stage thus prompt treatment is essential. Patients with a fever and a heart murmur should have blood cultures taken without delay before any antibiotic treatment is given. Patients with prosthetic valves who become feverish should be referred to a hospital with cardiology and, ideally, cardiothoracic surgery facilities and they should also have blood cultures taken before antibiotics are given.
A combination of a penicillin and an aminoglycoside, usually gentamicin, is still the most suitable first line treatment for streptococcal and most enterococcal and staphylococcal endocarditis. The type of penicillin, the dose, and the duration of treatment depend on the infecting organism and its in vitro antibiotic sensitivity, and this should be established as soon as possible. In patients who are allergic to penicillins one of the glycopeptide antibiotics, vancomycin or teicoplanin, should be used. We recommend similar treatment for native and prosthetic valve infections …
Footnotes
Keats House, Guys Hospital, London SE1 9RT, UK N A Simmons, Chairman until 23 January 1996
University of St Andrews, Division of Cell and Molecular Biology, St Andrews, Fife KY16 9AL, UK A P Ball
Division of Infection, UMDS, St Thomas’s Hospital, London SE1 7EH, UK S J Eykyn
Department of Cardiovascular Medicine, University of Birmingham, Birmingham B15 2TH, UK W A Littler, Chairman from 23 January 1996
Dental School, University of Glasgow, Glasgow G12 8QQ, UK D A McGowan
Department of Medicine (Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0NN, UK C M Oakley
Department of Medical Microbiology, Charing Cross and Westminster Medical School, London W6 8RP, UK D C Shanson